On March 27, 2022, Mark W. Mallon, member of the board of directors of NeoGenomics, Inc., stepped down from his positions as director, effective as of March 28, 2022. In connection with Mr. Mallon's departure, the board appointed Lynn A. Tetrault, Esq. the company's non-executive chair of the board and chair of the culture and compensation committee, to serve as executive chair and the company's principal executive officer.

Ms. Tetrault, as Executive Chair, will work together with the newly appointed “Office of the CEO,” comprised of the company's chief financial officer, chief culture officer and Chief Strategy and Corporate Development Officer, to discharge the duties and responsibilities of the chief executive officer.